News

VX-787 is an influenza A-specific, oral polymerase inhibitor designed to directly inhibit replication of the influenza A virus, including recent H1 and H5 influenza strains, based on in-vitro

Under the deal, Medison will market Glybera, uniQure’s gene therapy product for the treatment of lipoprotein lipase deficiency (LPLD), in Israel and the Palestinian Authority. Medison will also

Under the deal, Cipher has granted Andrómaco the exclusive right to market, sell and distribute its isotretinoin capsules in the country. After securing regulatory approval, it is expected

Under the deal, the company will be working with nanoRANCH’s Dan Dimitrijevich to create new treatment delivery methods using a combination of nanoRANCH technology and CRYO’s clinically processed

ProMetic’s PBI-4050 was found to be safe and very well tolerated without any serious adverse events reported in any of the 5 cohorts tested. The objectives of this

The patents, which expire in 2024, claim pharmaceutical compositions comprising a form of ferric citrate having an intrinsic dissolution rate of 1.88-4.0 mg/cm2/min, and orally administrable forms of

Radient’s facility, commissioned in January, 2014, is a 20,000 square foot manufacturing plant centered around Radient’s patented, proprietary technology, Microwave Assisted Processing ("MAP"). With MAP, Radient produces natural

This opinion paves the way for Plandaí to immediately commence sales efforts in the United States. The Federal Food, Drug and Cosmetic Act requires that the US FDA

Pegsiticase has shown the ability to efficiently reduce plasma uric acid levels in gout patients in successful U.S. Phase 1 clinical tests. The exclusive license enables Selecta to